Advertisement

Methods for Evaluation of Antiviral Efficacy Against Influenza Virus Infections in Animal Models

  • Donald F. Smee
  • Dale L. Barnard
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1030)

Abstract

Compounds undergoing preclinical development for anti-influenza virus activity require evaluation in small animal models. Laboratory mice are most commonly used for initial studies because of size, cost, and availability. Cotton rats, guinea pigs, and ferrets (particularly) have been used for more advanced studies. Each animal infection model has certain limitations relative to human influenza infections. For example, the fever response that is evident in humans only occurs with consistency in ferrets. Mice infected with mouse-adapted viruses and ferrets infected with highly pathogenic avian influenza viruses suffer severe disease, whereas cotton rats and guinea pigs manifest few symptoms. Thus, for each animal model there is a certain set of disease parameters that can be measured. Here we describe methods for assessing the efficacy of anti-influenza virus compounds in each of these animal species.

Key words

Influenza Antiviral Mice Cotton rats Guinea pigs Ferrets 

Notes

Acknowledgment

This work was funded in part with Federal funds from the Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201000039I/HHSN27200005/A37.

References

  1. 1.
    Sidwell RW, Smee DF (2004) Experimental disease models of influenza virus infections: recent developments. Drug Discov Today Dis Models 1:57–63CrossRefGoogle Scholar
  2. 2.
    Barnard DL (2009) Animal models for the study of influenza pathogenesis and therapy. Antiviral Res 82:A110–A122PubMedCrossRefGoogle Scholar
  3. 3.
    Zhang Y, Sun H, Fan L et al (2012) Acute respiratory distress syndrome induced by a swine 2009 H1N1 variant in mice. PLoS One 7(1):e29347PubMedCrossRefGoogle Scholar
  4. 4.
    Zhu W, Zhu Y, Qin K et al (2012) Mutations in polymerase genes enhanced the virulence of 2009 pandemic H1N1 influenza virus in mice. PLoS One 7(3):e33383PubMedCrossRefGoogle Scholar
  5. 5.
    Govorkova EA, Ilyushina NA, McClaren JL et al (2009) Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob Agents Chemother 53:3088–3096PubMedCrossRefGoogle Scholar
  6. 6.
    Sidwell RW, Bailey KW, Wong M-H, Barnard DL, Smee DF (2005) In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res 68:10–17PubMedCrossRefGoogle Scholar
  7. 7.
    Radigan KA, Urich D, Misharin AV et al (2012) The effect of rosuvastatin in a murine model of influenza a infection. PLoS One 7(4):e35788PubMedCrossRefGoogle Scholar
  8. 8.
    Yazawa K, Kurokawa M, Obuchi M et al (2011) Anti-influenza virus activity of tricin, 4′,5,7-trihydroxy-3′,5′-dimethoxyflavone. Antivir Chem Chemother 22:1–11PubMedCrossRefGoogle Scholar
  9. 9.
    Sidwell RW, Smee DF, Huffman JH, Barnard DL et al (2001) Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201. Antiviral Res 51:179–187PubMedCrossRefGoogle Scholar
  10. 10.
    Smee DF, Wong M-H, Bailey KW, Sidwell RW (2006) Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir Chem Chemother 17:185–192PubMedGoogle Scholar
  11. 11.
    Murray JL, McDonald NJ, Sheng J et al (2012) Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis. Antivir Chem Chemother 22:205–215PubMedCrossRefGoogle Scholar
  12. 12.
    Bantia S, Kellogg D, Parker C et al (2011) A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice. Antiviral Res 90:17–21PubMedCrossRefGoogle Scholar
  13. 13.
    Sidwell RW, Huffman JH, Call EW, Alaghamandan H, Robins RK (1986) Effect of selenazofurin on influenza A and B virus infections of mice. Antiviral Res 6:343–353PubMedCrossRefGoogle Scholar
  14. 14.
    Ryan DM, Ticehurst J, Dempsey MH, Penn CR (1994) Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother 38:2270–2275PubMedCrossRefGoogle Scholar
  15. 15.
    Ekiert DC, Friesen RHE, Babha G et al (2011) A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333:843–850PubMedCrossRefGoogle Scholar
  16. 16.
    Galabov AS, Simeonova L, Gegova G (2006) Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice. Antivir Chem Chemother 17:251–258PubMedGoogle Scholar
  17. 17.
    Sidwell RW, Huffman JH, Gilbert J et al (1992) Utilization of pulse oximetry for the study of the inhibitory effects of antiviral agents on influenza virus in mice. Antimicrob Agents Chemother 36:473–476PubMedCrossRefGoogle Scholar
  18. 18.
    Yoo DG, Kim MC, Park MK et al (2012) Protective effect of ginseng polysaccharides on influenza viral infection. PLoS One 7(3):e33678PubMedCrossRefGoogle Scholar
  19. 19.
    Sidwell RW, Barnard DL, Day CW, Smee DF et al (2007) Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 51:845–851PubMedCrossRefGoogle Scholar
  20. 20.
    Ilyushina NA, Hay A, Yilmaz N et al (2008) Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 52:3889–3897PubMedCrossRefGoogle Scholar
  21. 21.
    Kaminski MM, Ohnemus A, Cornitescu M, Staeheli P (2012) Plasmacytoid dendritic cells and Toll-like receptor 7-dependent signaling promote efficient protection of mice against highly virulent influenza A Virus. J Gen Virol 93:555–559PubMedCrossRefGoogle Scholar
  22. 22.
    Min JY, Vogel L, Matsuoka Y, Lu B et al (2010) A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys. J Virol 84:11950–11960PubMedCrossRefGoogle Scholar
  23. 23.
    Tarbet EB, Maekawa M, Furuta Y, Babu YS, Morrey JD, Smee DF (2012) Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. Antiviral Res 94:103–110PubMedCrossRefGoogle Scholar
  24. 24.
    Appleyard G, Maber HB (1974) Plaque formation by influenza viruses in the presence of trypsin. J Gen Virol 25:351–357PubMedCrossRefGoogle Scholar
  25. 25.
    Reed LJ, Muench H (1938) A simple method of estimating fifty per cent endpoints. Am J Hyg 27:493–498Google Scholar
  26. 26.
    Smee DF, Hurst BL, Wong M-H et al (2010) Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res 88:38–44PubMedCrossRefGoogle Scholar
  27. 27.
    Smee DF, Hurst BL, Wong M-H et al (2010) Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother 54:126–133PubMedCrossRefGoogle Scholar
  28. 28.
    Julander JG, Hagloch J, Latimer S, Motter N, Dagley A, Barnard DL, Smee DF, Morrey JD (2011) Use of plethysmography in assessing the efficacy of antivirals in a mouse model of pandemic influenza A virus. Antiviral Res 92:228–236PubMedCrossRefGoogle Scholar
  29. 29.
    Smee DF, Bailey KW, Wong M-H et al (2008) Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Antiviral Res 80:266–271PubMedCrossRefGoogle Scholar
  30. 30.
    Verhoeven D, Teijaro JR, Farber DL (2009) Pulse-oximetry accurately predicts lung pathology and the immune response during influenza infection. Virology 390:151–156PubMedCrossRefGoogle Scholar
  31. 31.
    Prichard MN, Shipman C Jr (1990) A three-dimensional model to analyze drug–drug interactions. Antiviral Res 14:181–205PubMedCrossRefGoogle Scholar
  32. 32.
    Ottolini MG, Blanco JC, Eichelberger MC et al (2005) The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis. J Gen Virol 86:2823–2830PubMedCrossRefGoogle Scholar
  33. 33.
    Lowen AC, Mubareka S, Tumpey TM et al (2006) The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci USA 103:9988–9992PubMedCrossRefGoogle Scholar
  34. 34.
    Govorkova EA, Rehg JE, Krauss S et al (2005) Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 79:2191–2198PubMedCrossRefGoogle Scholar
  35. 35.
    Govorkova EA, Marathe BM, Prevost A et al (2011) Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets. Antiviral Res 91:81–88PubMedCrossRefGoogle Scholar
  36. 36.
    Huang SS, Banner D, Fang Y et al (2011) Comparative analyses of pandemic H1N1 and seasonal H1N1, H3N2, and influenza B infections depict distinct clinical pictures in ferrets. PLoS One 6(11):e27512PubMedCrossRefGoogle Scholar
  37. 37.
    Boon AC, Finkelstein D, Zheng M et al (2011) H5N1 influenza virus pathogenesis in genetically diverse mice is mediated at the level of viral load. MBio 2(5):e00171-11PubMedCrossRefGoogle Scholar
  38. 38.
    Otte A, Sauter M, Alleva L et al (2011) Differential host determinants contribute to the pathogenesis of 2009 pandemic H1N1 and human H5N1 influenza A viruses in experimental mouse models. Am J Pathol 179:230–239PubMedCrossRefGoogle Scholar
  39. 39.
    Sidwell RW, Smee DF, Huffman JH, Barnard DL et al (2001) In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob Agents Chemother 45:749–757PubMedCrossRefGoogle Scholar
  40. 40.
    Smee DF, Wandersee MK, Wong M-H et al (2004) Treatment of mannan-enhanced influenza B virus infections in mice with oseltamivir, ribavirin and viramidine. Antivir Chem Chemother 15:261–268PubMedGoogle Scholar
  41. 41.
    Southam DS, Dolovich M, O'Byrne PM, Inman MD (2002) Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am J Physiol Lung Cell Mol Physiol 282:L833–L839PubMedGoogle Scholar
  42. 42.
    Nguyen JT, Smee DF, Barnard DL et al (2012) Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS One 7(1):e31006PubMedCrossRefGoogle Scholar
  43. 43.
    Bantia S, Kellogg D, Parker CD, Babu YS (2010) Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model. Antiviral Res 88:276–280PubMedCrossRefGoogle Scholar
  44. 44.
    Smee DF, von Itzstein M, Bhatt B, Tarbet EB (2012) Exacerbation of influenza virus infections in mice by intranasal treatments and implications for evaluation of antiviral drugs. Antimicrob Agents Chemother 56:6328–6333CrossRefGoogle Scholar
  45. 45.
    Motulsky H (1995) Comparing two proportions. In: Motulsky H (ed) Intuitive biostatistics. Oxford University Press, New York, pp 235–236Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Donald F. Smee
    • 1
  • Dale L. Barnard
    • 1
  1. 1.Department of Animal, Dairy, and Veterinary SciencesInstitute for Antiviral Research, Utah State UniversityLoganUSA

Personalised recommendations